Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma

✍ Scribed by Nozomi Niitsu; Mika Kohri; Yuki Hagiwara; Ken Tanae; Naoki Takahashi; Masami Bessho; Masataka Okamoto

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 184 KB
• Volume: 28
• Category: Article
• ISSN: 0278-0232
• DOI: 10.1002/hon.940

✦ Synopsis

Abstract

The R‐CHOP regimen has been found to improve the outcome of diffuse large B‐cell lymphoma (DLBCL). However, it does not provide a satisfactory treatment outcome in the high‐risk group. We previously administered the CyclOBEAP regimen to patients with DLBCL, and reported its safety and efficacy. The R‐CyclOBEAP regimen was administered over a total period of 12 weeks, and rituximab 375 mg/m^2^ was given every 2 weeks. There were 101 eligible patients. CR was achieved in 96 patients (95%). The 5‐year overall survival (OS) rate was 85% and progression‐free survival (PFS) rate was 76%. When the patients were divided according to the IPI, the 5‐year OS and PFS rates did not significantly differ among the risk groups. The 5‐year PFS of the germinal centre B‐cell group was 80% and that of the non‐GCB group was 74% (NS). Univariate analysis showed that the presence of B symptoms, extranodal lesions ≧2, and sIL‐2R were significant poor prognostic factors. Grade 4 neutropenia was observed in 91 patients and thrombocytopenia in 9 patients. The addition of rituximab to CyclOBEAP therapy may enhance the effect of CyclOBEAP therapy for DLBCL. Copyright © 2010 John Wiley & Sons, Ltd.